Teresa Garriga-Baraut, Moises Labrador-Horrillo, Mercé Tena, Concepción De Linares, Olga Esteso-Hontoria, Carlos Pedemonte, Maria Basagaña-Torrento, Sira Miquel, Clara Padró-Casas, Núria Campa-Falcon, Laia Ferré-Ybarz, Vanessa Gázquez-Garcia, Rosa Muñoz-Cano, Marta Viñas, Lidia Farrarons, Miquel Baltasar-Dragó, Núria Cortés, Oscar Asensio, Joan Bartra, Jordina Belmonte, Irina Bobolea, Esperanza Raga, Mar San Miguel Moncín
{"title":"一项真实的 ImmunoCAT 研究：通过 ImmunoCAPTM ISAC 112 进行分子诊断对西班牙加泰罗尼亚花粉过敏患者免疫疗法处方的影响。","authors":"Teresa Garriga-Baraut, Moises Labrador-Horrillo, Mercé Tena, Concepción De Linares, Olga Esteso-Hontoria, Carlos Pedemonte, Maria Basagaña-Torrento, Sira Miquel, Clara Padró-Casas, Núria Campa-Falcon, Laia Ferré-Ybarz, Vanessa Gázquez-Garcia, Rosa Muñoz-Cano, Marta Viñas, Lidia Farrarons, Miquel Baltasar-Dragó, Núria Cortés, Oscar Asensio, Joan Bartra, Jordina Belmonte, Irina Bobolea, Esperanza Raga, Mar San Miguel Moncín","doi":"10.15586/aei.v52i4.1077","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients.</p><p><strong>Objective: </strong>To assess the impact of molecular diagnosis through the ImmunoCAP<sup>TM</sup> ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species.</p><p><strong>Methods: </strong>A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient's clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAP<sup>TM</sup> ISAC<sup>®</sup> 112 to recombinant and/or purified allergen components.</p><p><strong>Results: </strong>A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray.</p><p><strong>Conclusions: </strong>Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"52 4","pages":"21-29"},"PeriodicalIF":2.5000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A real-life ImmunoCAT study: impact of molecular diagnosis through ImmunoCAP<sup>TM</sup> ISAC 112 on immunotherapy prescription in pollen-polysensitized patients in Catalonia, Spain.\",\"authors\":\"Teresa Garriga-Baraut, Moises Labrador-Horrillo, Mercé Tena, Concepción De Linares, Olga Esteso-Hontoria, Carlos Pedemonte, Maria Basagaña-Torrento, Sira Miquel, Clara Padró-Casas, Núria Campa-Falcon, Laia Ferré-Ybarz, Vanessa Gázquez-Garcia, Rosa Muñoz-Cano, Marta Viñas, Lidia Farrarons, Miquel Baltasar-Dragó, Núria Cortés, Oscar Asensio, Joan Bartra, Jordina Belmonte, Irina Bobolea, Esperanza Raga, Mar San Miguel Moncín\",\"doi\":\"10.15586/aei.v52i4.1077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients.</p><p><strong>Objective: </strong>To assess the impact of molecular diagnosis through the ImmunoCAP<sup>TM</sup> ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species.</p><p><strong>Methods: </strong>A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient's clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAP<sup>TM</sup> ISAC<sup>®</sup> 112 to recombinant and/or purified allergen components.</p><p><strong>Results: </strong>A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray.</p><p><strong>Conclusions: </strong>Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"52 4\",\"pages\":\"21-29\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v52i4.1077\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v52i4.1077","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
A real-life ImmunoCAT study: impact of molecular diagnosis through ImmunoCAPTM ISAC 112 on immunotherapy prescription in pollen-polysensitized patients in Catalonia, Spain.
Background: Molecular diagnosis in allergology helps to identify multiple allergenic molecules simultaneously. The use of purified and/or recombinant allergens increases the accuracy of individual sensitization profiles in allergic patients.
Objective: To assess the impact of molecular diagnosis through the ImmunoCAPTM ISAC 112 microarray on etiological diagnosis and specific immunotherapy (SIT) prescription. This was compared to the use of conventional diagnoses in pediatric, adolescent, and young adult patients with rhinitis or rhinoconjunctivitis and/or allergic asthma, sensitized to three or more pollen allergens of different botanical species.
Methods: A multicenter, prospective, observational study was conducted in patients aged 3-25 years who received care at the Allergology service of 14 hospitals in Catalonia from 2017 to 2020. Allergology diagnosis was established based on the patient's clinical assessment and the results of the skin prick test and specific immunoglobulin E assays. Subsequently, molecular diagnosis was conducted using ImmunoCAPTM ISAC® 112 to recombinant and/or purified allergen components.
Results: A total of 109 patients were included; 35 (32.1%) were pediatric patients and 74 (67.9%) were adolescents or young adults (mean age: 18 years), with 58.0% being females. A change of 51.0% was observed in SIT prescription following molecular etiological diagnosis by means of a multi-parameter microarray.
Conclusions: Molecular diagnosis by means of multi-parameter tests increases the accuracy of etiological diagnosis and helps to define an accurate composition of SIT.
期刊介绍：
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
